Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 4 1

Status

Completed 3Terminated 2Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Sarcoma 1Gastrointestinal 1

Conditions

Breast Neoplasms 1278Carcinoma, Non-Small-Cell Lung 927Prostatic Neoplasms 729Neoplasms 633Multiple Myeloma 554Lymphoma 540Colorectal Neoplasms 530Lung Neoplasms 515Leukemia 498Leukemia, Myeloid, Acute 474Neoplasm Metastasis 471Melanoma 426Lymphoma, Non-Hodgkin 420Ovarian Neoplasms 417Leukemia, Lymphocytic, Chronic, B-Cell 386Pancreatic Neoplasms 373Recurrence 338Precursor Cell Lymphoblastic Leukemia-Lymphoma 329Head and Neck Neoplasms 307Lymphoma, Large B-Cell, Diffuse 295Glioblastoma 294Myelodysplastic Syndromes 288Lymphoma, Follicular 287Brain Neoplasms 287Stomach Neoplasms 282Carcinoma, Renal Cell 268Carcinoma, Hepatocellular 262Hodgkin Disease 261Rectal Neoplasms 256Sarcoma 250

Interventions

Denosumab 2Vitamin D 1Dasatinib 1Calcium 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Completed × Giant Cell Tumor of Bone × Clear all
NCT00396279 2022-11-08

Safety and Efficacy Study of Denosumab in Patients With Recurrent or Unresectable Giant Cell Tumor of Bone

Amgen

Phase 2 Completed
37 enrolled 13 charts

Giant Cell Tumor of Bone

NCT00680992 2022-09-22

Study of Denosumab in Subjects With Giant Cell Tumor of Bone

Amgen

Phase 2 Completed
535 enrolled 16 charts

Giant Cell Tumors, Neoplasms, Giant Cell Tumor of Bone

NCT00464620 2018-11-23

Trial of Dasatinib in Advanced Sarcomas

Sarcoma Alliance for Research through Collaboration

Phase 2 Completed
366 enrolled 16 charts
GastrointestinalSarcoma

Chondrosarcoma, Chordoma, Hemangiopericytoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Giant Cell Tumor of Bone, Sarcoma, Alveolar Soft Part, Neurofibrosarcoma, Gastrointestinal Stromal Tumors, Solitary Fibrous Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡